288 related articles for article (PubMed ID: 28202629)
1. Improving the In Silico Assessment of Proarrhythmia Risk by Combining hERG (Human Ether-à-go-go-Related Gene) Channel-Drug Binding Kinetics and Multichannel Pharmacology.
Li Z; Dutta S; Sheng J; Tran PN; Wu W; Chang K; Mdluli T; Strauss DG; Colatsky T
Circ Arrhythm Electrophysiol; 2017 Feb; 10(2):e004628. PubMed ID: 28202629
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
3. A history of the role of the hERG channel in cardiac risk assessment.
Rampe D; Brown AM
J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
[TBL] [Abstract][Full Text] [Related]
4. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.
Hoffmann P; Warner B
J Pharmacol Toxicol Methods; 2006; 53(2):87-105. PubMed ID: 16289936
[TBL] [Abstract][Full Text] [Related]
5. Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Mirams GR; Cui Y; Sher A; Fink M; Cooper J; Heath BM; McMahon NC; Gavaghan DJ; Noble D
Cardiovasc Res; 2011 Jul; 91(1):53-61. PubMed ID: 21300721
[TBL] [Abstract][Full Text] [Related]
6. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
Eur J Pharmacol; 2007 Dec; 577(1-3):222-32. PubMed ID: 18074444
[TBL] [Abstract][Full Text] [Related]
7. QT interval prolongation and cardiac risk assessment for novel drugs.
Picard S; Lacroix P
Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
[TBL] [Abstract][Full Text] [Related]
8. Torsadogenic cardiotoxicity of antipsychotic drugs: a structural feature, potentially involved in the interaction with cardiac HERG potassium channels.
Testai L; Bianucci AM; Massarelli I; Breschi MC; Martinotti E; Calderone V
Curr Med Chem; 2004 Oct; 11(20):2691-706. PubMed ID: 15544470
[TBL] [Abstract][Full Text] [Related]
9. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
10. Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade.
Deacon M; Singleton D; Szalkai N; Pasieczny R; Peacock C; Price D; Boyd J; Boyd H; Steidl-Nichols JV; Williams C
J Pharmacol Toxicol Methods; 2007; 55(3):238-47. PubMed ID: 17141530
[TBL] [Abstract][Full Text] [Related]
11. Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety.
Gintant GA; Su Z; Martin RL; Cox BF
Toxicol Pathol; 2006; 34(1):81-90. PubMed ID: 16507548
[TBL] [Abstract][Full Text] [Related]
12. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
Polak S; Wiśniowska B; Brandys J
J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
[TBL] [Abstract][Full Text] [Related]
13. High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.
Di Veroli GY; Davies MR; Zhang H; Abi-Gerges N; Boyett MR
Am J Physiol Heart Circ Physiol; 2013 Jan; 304(1):H104-17. PubMed ID: 23103500
[TBL] [Abstract][Full Text] [Related]
14. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
Eur J Pharmacol; 2006 Dec; 553(1-3):229-39. PubMed ID: 17054943
[TBL] [Abstract][Full Text] [Related]
15. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.
Hanson LA; Bass AS; Gintant G; Mittelstadt S; Rampe D; Thomas K
J Pharmacol Toxicol Methods; 2006; 54(2):116-29. PubMed ID: 16843688
[TBL] [Abstract][Full Text] [Related]
16. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
17. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
18. hERG-related drug toxicity and models for predicting hERG liability and QT prolongation.
Raschi E; Ceccarini L; De Ponti F; Recanatini M
Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1005-21. PubMed ID: 19572824
[TBL] [Abstract][Full Text] [Related]
19. A rabbit Langendorff heart proarrhythmia model: predictive value for clinical identification of Torsades de Pointes.
Lawrence CL; Bridgland-Taylor MH; Pollard CE; Hammond TG; Valentin JP
Br J Pharmacol; 2006 Dec; 149(7):845-60. PubMed ID: 17031389
[TBL] [Abstract][Full Text] [Related]
20. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
Jacobson I; Carlsson L; Duker G
J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
